Literature DB >> 2231067

Adult immunizations: are they worth the trouble?

F M LaForce1.   

Abstract

There are good data to recommend routine use of vaccines against measles, rubella, tetanus, influenza, and pneumococcal infections in adults. An adolescent or an adult born after 1956 is considered to be susceptible to measles unless he or she has received two doses of live measles vaccine or has suffered a physician-diagnosed case of measles. Tetanus is largely a disease of the elderly, and there is a universal need for immunizations with tetanus toxoid. Influenza continues to be a major public health problem, and influenza vaccine should be given annually to the elderly and to those at high risk. The efficacy of pneumococcal vaccine in American adults is still being debated. Results from case-control studies show that the vaccine is about 60% effective in reducing the incidence of disease due to vaccine-related strains. Its use in the elderly and in those at higher risk for pneumococcal infection is recommended.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2231067     DOI: 10.1007/bf02600844

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  17 in total

1.  Rubella and congenital rubella syndrome--United States, 1985-1988.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-03-24       Impact factor: 17.586

Review 2.  Immunization policies and vaccine coverage among adults. The risk for missed opportunities.

Authors:  W W Williams; M A Hickson; M A Kane; A P Kendal; J S Spika; A R Hinman
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

3.  Bacterial pneumonia in patients with the acquired immunodeficiency syndrome.

Authors:  B Polsky; J W Gold; E Whimbey; J Dryjanski; A E Brown; G Schiffman; D Armstrong
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

4.  Inefficacy of pneumococcal vaccine in a high-risk population.

Authors:  H L Forrester; D W Jahnigen; F M LaForce
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

5.  The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial.

Authors:  K W Newell; A Dueñas Lehmann; D R LeBlanc; N Garces Osorio
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

6.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.

Authors:  M S Simberkoff; A P Cross; M Al-Ibrahim; A L Baltch; P J Geiseler; J Nadler; A S Richmond; R P Smith; G Schiffman; D S Shepard
Journal:  N Engl J Med       Date:  1986-11-20       Impact factor: 91.245

7.  Pneumococcal disease in a medium-sized community in the United States.

Authors:  M A Mufson; G Oley; D Hughey
Journal:  JAMA       Date:  1982-09-24       Impact factor: 56.272

Review 8.  Pneumococcal vaccine.

Authors:  F M LaForce
Journal:  Semin Respir Infect       Date:  1989-12

9.  Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982.

Authors:  G Meiklejohn
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

Review 10.  Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

Authors:  R Austrian
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr
View more
  4 in total

1.  Development of an immunization tracking system in a large health maintenance organization. Group Health Cooperative of Puget Sound.

Authors:  T Payne; S Kanvik; R Seward; D Beeman; A Salazar; Z Miller; V Immanuel; R S Thompson
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1991

Review 2.  The cost effectiveness of pneumococcal vaccination strategies.

Authors:  C B Gable; M Botteman; G Savage; K Joy
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

3.  Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis.

Authors:  D J Balestra; B Littenberg
Journal:  J Gen Intern Med       Date:  1993-08       Impact factor: 5.128

Review 4.  Vaccination of adults against travel-related infectious diseases, and new developments in vaccines.

Authors:  P C Döller
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.